KRM Ayurveda IPO

KRM Ayurveda IPO is a book-building IPO of ₹77.49 cr, which is entirely a fresh issue of shares. The price band is set at ₹128 to ₹135 per share and the lot size for an application is 1,000. The IPO is finalized to be open for subscription on January 19, 2026 and closes on January 21, 2026. KRM Ayurveda IPO will list on the NSE SME platform with a tentative listing date fixed as January 27, 2026.

Company Background

KRM Ayurveda Ltd. was founded on September 3, 2019. They are a Delhi-based leading Ayurvedic health care facility. The company is dedicated to changing the “healing intensity” of Ayurveda through a diverse system, with 6 multispecialty hospitals and 5 clinics spanning India. Focusing on individualized care for chronic conditions such as kidney issues and lifestyle diseases, KRM Ayurveda blends classical Panchakarma and Sattvic dietetics with contemporary health. The firm also produces over 300 GMP certified herbal products, as well as providing global teleconsultation services and has within it an established base with over 150,000 customers worldwide focussing on holistic relationships between mind, body and soul.

Operations and Product Range

Facility and Production

This is a professionally managed health care network that has 6 multi-specialty hospitals and 5 clinics located in various parts of India. Its manufacturing arm churns out more than 300 GMP-certified Ayurvedic products ranging from patented medicaments to skin care. With ancient Panchakarma treatment rooms combined with the modern clinical laboratories, these centers provide high-quality and genuine Ayurvedic treatments to over 150,000 patients annually.

Brands and Market Presence

KRM Ayurveda, also known as Karma Ayurveda, has been a familiar brand since 1937 for kidney care and chronic care. The company also sells a consumer line called AyuKarma with more than 300 GMP-certified products, including Shilajit Resin and Arsh Karma. This startup has significant competition in Delhi, Gurugram and Jaipur. They also make their service available to the whole world through teleconsultation and clinics in the UK, UAE and the USA.

Revenue Channels

• • The main source of revenue is IPD and OPD services across 11 facilities.
• • This company sells ayurvedic medicines and wellness products via its dispensaries
• • Tele-consulting services have become a source of revenue for the firm.

Management and Shareholding

Promoters and Shareholding

The company is led by its promoters, Mr. Puneet Dhawan and Mrs. Tanya Dhawan, who maintain a dominant controlling interest. Before the IPO, the promoter group held 92.15% of the company's equity shares. Post-issue, their stake will adjust to accommodate the new public shareholders as the company transitions to being listed on the NSE SME platform.

Board Members

The board members of this company aim to globalise authentic Ayurveda by integrating traditional expertise with modern clinical standards. Members' vision centers on scaling specialized kidney and chronic care through the "Heal in India" initiative. They collectively work for the growth of the company by contributing medical authority, operational excellence and robust corporate governance.